 | • レポートコード：QFJ1-5796 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、特発性過眠症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（覚せい剤、覚せい剤覚醒促進剤、オキシン酸ナトリウム）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・特発性過眠症治療の市場動向 ・企業の競争状況、市場シェア ・特発性過眠症治療の種類別市場規模と予測2016-2027（覚せい剤、覚せい剤覚醒促進剤、オキシン酸ナトリウム） ・特発性過眠症治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・特発性過眠症治療の北米市場規模2016-2027（アメリカ、カナダ） ・特発性過眠症治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・特発性過眠症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・特発性過眠症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・特発性過眠症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Takeda Pharmaceutical、Teva Pharmaceutical Industries、Jazz Pharmaceuticals、BIOPROJET、Avadel Pharmaceuticals、GlaxoSmithKline、Pfizer、Theranexus、Fisher and Paykel Healthcare、Drive DeVilbiss Healthcare、Merck） ・結論 |
Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.
Market Analysis and Insights: Global Idiopathic Hypersomnia Treatment Market
The global Idiopathic Hypersomnia Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Idiopathic Hypersomnia Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Idiopathic Hypersomnia Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Idiopathic Hypersomnia Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Idiopathic Hypersomnia Treatment market.
Global Idiopathic Hypersomnia Treatment Scope and Market Size
Idiopathic Hypersomnia Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Hypersomnia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Stimulant Medications
Non-Stimulant Wake-Promoting Medications
Sodium Oxybate
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Jazz Pharmaceuticals
BIOPROJET
Avadel Pharmaceuticals
GlaxoSmithKline
Pfizer
Theranexus
Fisher and Paykel Healthcare
Drive DeVilbiss Healthcare
Merck
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Stimulant Medications
1.2.3 Non-Stimulant Wake-Promoting Medications
1.2.4 Sodium Oxybate
1.3 Market by Application
1.3.1 Global Idiopathic Hypersomnia Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2016-2027)
2.2 Idiopathic Hypersomnia Treatment Growth Trends by Regions
2.2.1 Idiopathic Hypersomnia Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Idiopathic Hypersomnia Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Idiopathic Hypersomnia Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Idiopathic Hypersomnia Treatment Industry Dynamic
2.3.1 Idiopathic Hypersomnia Treatment Market Trends
2.3.2 Idiopathic Hypersomnia Treatment Market Drivers
2.3.3 Idiopathic Hypersomnia Treatment Market Challenges
2.3.4 Idiopathic Hypersomnia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue
3.1.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue (2016-2021)
3.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Idiopathic Hypersomnia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Hypersomnia Treatment Revenue
3.4 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Hypersomnia Treatment Revenue in 2020
3.5 Idiopathic Hypersomnia Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Hypersomnia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Hypersomnia Treatment Breakdown Data by Type
4.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2016-2021)
4.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2022-2027)
5 Idiopathic Hypersomnia Treatment Breakdown Data by Application
5.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2016-2021)
5.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Idiopathic Hypersomnia Treatment Market Size (2016-2027)
6.2 North America Idiopathic Hypersomnia Treatment Market Size by Type
6.2.1 North America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021)
6.2.2 North America Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027)
6.2.3 North America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2027)
6.3 North America Idiopathic Hypersomnia Treatment Market Size by Application
6.3.1 North America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021)
6.3.2 North America Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027)
6.3.3 North America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2027)
6.4 North America Idiopathic Hypersomnia Treatment Market Size by Country
6.4.1 North America Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021)
6.4.2 North America Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Idiopathic Hypersomnia Treatment Market Size (2016-2027)
7.2 Europe Idiopathic Hypersomnia Treatment Market Size by Type
7.2.1 Europe Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021)
7.2.2 Europe Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027)
7.2.3 Europe Idiopathic Hypersomnia Treatment Market Size by Type (2016-2027)
7.3 Europe Idiopathic Hypersomnia Treatment Market Size by Application
7.3.1 Europe Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021)
7.3.2 Europe Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027)
7.3.3 Europe Idiopathic Hypersomnia Treatment Market Size by Application (2016-2027)
7.4 Europe Idiopathic Hypersomnia Treatment Market Size by Country
7.4.1 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021)
7.4.2 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2016-2027)
8.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type
8.2.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application
8.3.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region
8.4.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Idiopathic Hypersomnia Treatment Market Size (2016-2027)
9.2 Latin America Idiopathic Hypersomnia Treatment Market Size by Type
9.2.1 Latin America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2027)
9.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Application
9.3.1 Latin America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2027)
9.4 Latin America Idiopathic Hypersomnia Treatment Market Size by Country
9.4.1 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2016-2027)
10.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type
10.2.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application
10.3.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country
10.4.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Takeda Pharmaceutical
11.1.1 Takeda Pharmaceutical Company Details
11.1.2 Takeda Pharmaceutical Business Overview
11.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Introduction
11.1.4 Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.1.5 Takeda Pharmaceutical Recent Development
11.2 Teva Pharmaceutical Industries
11.2.1 Teva Pharmaceutical Industries Company Details
11.2.2 Teva Pharmaceutical Industries Business Overview
11.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Introduction
11.2.4 Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.2.5 Teva Pharmaceutical Industries Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Details
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 BIOPROJET
11.4.1 BIOPROJET Company Details
11.4.2 BIOPROJET Business Overview
11.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Introduction
11.4.4 BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.4.5 BIOPROJET Recent Development
11.5 Avadel Pharmaceuticals
11.5.1 Avadel Pharmaceuticals Company Details
11.5.2 Avadel Pharmaceuticals Business Overview
11.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
11.5.4 Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.5.5 Avadel Pharmaceuticals Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Idiopathic Hypersomnia Treatment Introduction
11.7.4 Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 Theranexus
11.8.1 Theranexus Company Details
11.8.2 Theranexus Business Overview
11.8.3 Theranexus Idiopathic Hypersomnia Treatment Introduction
11.8.4 Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.8.5 Theranexus Recent Development
11.9 Fisher and Paykel Healthcare
11.9.1 Fisher and Paykel Healthcare Company Details
11.9.2 Fisher and Paykel Healthcare Business Overview
11.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Introduction
11.9.4 Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.9.5 Fisher and Paykel Healthcare Recent Development
11.10 Drive DeVilbiss Healthcare
11.10.1 Drive DeVilbiss Healthcare Company Details
11.10.2 Drive DeVilbiss Healthcare Business Overview
11.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Introduction
11.10.4 Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.10.5 Drive DeVilbiss Healthcare Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Idiopathic Hypersomnia Treatment Introduction
11.11.4 Merck Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021)
11.11.5 Merck Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Stimulant Medications
Table 3. Key Players of Non-Stimulant Wake-Promoting Medications
Table 4. Key Players of Sodium Oxybate
Table 5. Global Idiopathic Hypersomnia Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Idiopathic Hypersomnia Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Idiopathic Hypersomnia Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Idiopathic Hypersomnia Treatment Market Share by Regions (2016-2021)
Table 9. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Idiopathic Hypersomnia Treatment Market Share by Regions (2022-2027)
Table 11. Idiopathic Hypersomnia Treatment Market Trends
Table 12. Idiopathic Hypersomnia Treatment Market Drivers
Table 13. Idiopathic Hypersomnia Treatment Market Challenges
Table 14. Idiopathic Hypersomnia Treatment Market Restraints
Table 15. Global Idiopathic Hypersomnia Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Idiopathic Hypersomnia Treatment Market Share by Players (2016-2021)
Table 17. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2020)
Table 18. Ranking of Global Top Idiopathic Hypersomnia Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Idiopathic Hypersomnia Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
Table 22. Date of Enter into Idiopathic Hypersomnia Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Idiopathic Hypersomnia Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Takeda Pharmaceutical Company Details
Table 63. Takeda Pharmaceutical Business Overview
Table 64. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product
Table 65. Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 66. Takeda Pharmaceutical Recent Development
Table 67. Teva Pharmaceutical Industries Company Details
Table 68. Teva Pharmaceutical Industries Business Overview
Table 69. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product
Table 70. Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 71. Teva Pharmaceutical Industries Recent Development
Table 72. Jazz Pharmaceuticals Company Details
Table 73. Jazz Pharmaceuticals Business Overview
Table 74. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 75. Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 76. Jazz Pharmaceuticals Recent Development
Table 77. BIOPROJET Company Details
Table 78. BIOPROJET Business Overview
Table 79. BIOPROJET Idiopathic Hypersomnia Treatment Product
Table 80. BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 81. BIOPROJET Recent Development
Table 82. Avadel Pharmaceuticals Company Details
Table 83. Avadel Pharmaceuticals Business Overview
Table 84. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product
Table 85. Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 86. Avadel Pharmaceuticals Recent Development
Table 87. GlaxoSmithKline Company Details
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product
Table 90. GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Pfizer Company Details
Table 93. Pfizer Business Overview
Table 94. Pfizer Idiopathic Hypersomnia Treatment Product
Table 95. Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 96. Pfizer Recent Development
Table 97. Theranexus Company Details
Table 98. Theranexus Business Overview
Table 99. Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 100. Theranexus Recent Development
Table 101. Fisher and Paykel Healthcare Company Details
Table 102. Fisher and Paykel Healthcare Business Overview
Table 103. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product
Table 104. Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 105. Fisher and Paykel Healthcare Recent Development
Table 106. Drive DeVilbiss Healthcare Company Details
Table 107. Drive DeVilbiss Healthcare Business Overview
Table 108. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product
Table 109. Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 110. Drive DeVilbiss Healthcare Recent Development
Table 111. Merck Company Details
Table 112. Merck Business Overview
Table 113. Merck Idiopathic Hypersomnia Treatment Product
Table 114. Merck Revenue in Idiopathic Hypersomnia Treatment Business (2016-2021) & (US$ Million)
Table 115. Merck Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Hypersomnia Treatment Market Share by Type: 2020 VS 2027
Figure 2. Stimulant Medications Features
Figure 3. Non-Stimulant Wake-Promoting Medications Features
Figure 4. Sodium Oxybate Features
Figure 5. Global Idiopathic Hypersomnia Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Idiopathic Hypersomnia Treatment Report Years Considered
Figure 10. Global Idiopathic Hypersomnia Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Idiopathic Hypersomnia Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Idiopathic Hypersomnia Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Idiopathic Hypersomnia Treatment Market Share by Regions (2022-2027)
Figure 14. Global Idiopathic Hypersomnia Treatment Market Share by Players in 2020
Figure 15. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Idiopathic Hypersomnia Treatment Revenue in 2020
Figure 17. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Idiopathic Hypersomnia Treatment Market Share by Type (2016-2027)
Figure 21. North America Idiopathic Hypersomnia Treatment Market Share by Application (2016-2027)
Figure 22. North America Idiopathic Hypersomnia Treatment Market Share by Country (2016-2027)
Figure 23. United States Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Idiopathic Hypersomnia Treatment Market Share by Type (2016-2027)
Figure 27. Europe Idiopathic Hypersomnia Treatment Market Share by Application (2016-2027)
Figure 28. Europe Idiopathic Hypersomnia Treatment Market Share by Country (2016-2027)
Figure 29. Germany Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Region (2016-2027)
Figure 39. China Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Idiopathic Hypersomnia Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Idiopathic Hypersomnia Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Idiopathic Hypersomnia Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Idiopathic Hypersomnia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Takeda Pharmaceutical Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 59. Teva Pharmaceutical Industries Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 60. Jazz Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 61. BIOPROJET Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 62. Avadel Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 64. Pfizer Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 65. Theranexus Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 66. Fisher and Paykel Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 67. Drive DeVilbiss Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 68. Merck Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
世界の調剤薬局市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Compounding Pharmacies Market The global Compounding Pharmacies market size is projected to reach US$ 13500 million by 2027, from US$ 11180 million in 2020, at a CAGR of 2.7% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, t…- 世界の禁煙用医薬品市場規模・現状・予測（2021年-2027年） Smoking cessation drugs are de-addiction drugs for smoking. The alkaloid compound called nicotine causes addictive dependency on cigarettes and other smoking products. Smoking cessation results in withdrawal symptoms such as anxiety, strong cravings, depressing mood, insomnia and mood alterations. M…
- 世界の特発性肺線維症治療市場規模・現状・予測（2021年-2027年） Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff. Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Treatment Market The global Idiopathic Pulmonary Fibrosis Treatment market size is projected to reach…
- 世界の慢性特発性便秘治療市場規模・現状・予測（2021年-2027年） Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage …
- 世界の特発性頭蓋内圧亢進症治療薬市場規模・現状・予測（2021年-2027年） A drug used to treat idiopathic intracranial hypertension. Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Therapeutics Market The global Idiopathic Intracranial Hypertension Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020,…